[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 119
1. Argote-Greene LM, Chang MY, Sugarbaker DJ: Extrapleural pneumonectomy for malignant pleural mesothelioma. Multimed Man Cardiothorac Surg; 2005 Jan 1;2005(628):mmcts.2004.000133
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapleural pneumonectomy for malignant pleural mesothelioma.
  • Over the past 20 years, the extrapleural pneumonectomy technique has been modified and applied to the treatment of locally advanced malignant pleural mesothelioma, achieving substantial reductions in mortality.
  • The current mortality rate of 3.4% at the Brigham and Women's Hospital has permitted us to expand our use of this operation to treat locally advanced lung cancer and thymoma.
  • The technique discussed below is the culmination of 20 years' experience with malignant pleural mesothelioma at the Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston, MA USA.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24414726.001).
  • [Journal-full-title] Multimedia manual of cardiothoracic surgery : MMCTS
  • [ISO-abbreviation] Multimed Man Cardiothorac Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Sato A, Torii I, Okamura Y, Yamamoto T, Nishigami T, Kataoka TR, Song M, Hasegawa S, Nakano T, Kamei T, Tsujimura T: Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol; 2010 Nov;23(11):1458-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.
  • Malignant pleural mesothelioma is a refractory tumor with poor prognosis associated with asbestos exposure.
  • Pleural effusion is frequently observed in patients with malignant pleural mesothelioma, and cytological analysis is effective to detect malignant pleural mesothelioma.
  • However, cytological discrimination between malignant pleural mesothelioma and reactive mesothelium is often difficult.
  • Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer.
  • In this study, to evaluate the diagnostic utility of CD146 for discrimination between malignant pleural mesothelioma and reactive mesothelium, we examined immunocytochemical expression of CD146 in malignant pleural mesothelioma and reactive mesothelium using two clones of CD146 antibody, OJ79 and EPR3208, on smear specimens of effusion fluids.
  • CD146 expression was detected in 15 of 16 malignant pleural mesothelioma with median immunostaining score of 3 by OJ79, and in 19 of 21 malignant pleural mesothelioma with median immunostaining score of 2 by EPR3208.
  • Strong immunoreactivity of CD146 was observed at the apposing surfaces of cell-cell interactions on the plasma membrane of mesothelioma cells.
  • In addition, one OJ79-negative case of malignant pleural mesothelioma was positive for CD146 by EPR3208 and two EPR3208-negative cases of malignant pleural mesothelioma were CD146 positive by OJ79, showing that all 23 malignant pleural mesothelioma cases were positive for CD146 by either OJ79 or EPR3208.
  • We propose that CD146 is a sensitive and specific immunocytochemical marker enabling differential diagnosis of malignant pleural mesothelioma from reactive mesothelium.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epithelium / immunology. Immunohistochemistry. Mesothelioma / immunology. Pleural Effusion, Malignant / immunology. Pleural Neoplasms / immunology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657552.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD146; 0 / Biomarkers, Tumor; 0 / MCAM protein, human
  •  go-up   go-down


3. Ramalingam SS, Belani CP: Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol; 2008 Sep;3(9):1056-64
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the treatment of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma clinically manifests after decades of initial exposure to etiologic agents, such as asbestos, and presents with nonspecific symptoms such as dyspnea, pain, or weight loss.
  • The combination of cisplatin and pemetrexed, a novel multitargeted antifolate agent, is the approved "standard of care" for patients with unresectable malignant pleural mesothelioma.
  • A number of molecularly targeted agents are currently under evaluation for mesothelioma such as the Histone deacetylase (HDAC) inhibitors that have demonstrated promising anticancer activity.
  • Vorinostat, a small molecule inhibitor of HDAC, which targets select members of class I and II HDACs, has shown early evidence of activity and is currently being evaluated in a randomized study for patients who progress with standard therapy for advanced mesothelioma.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758312.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


Advertisement
4. Tomasetti M, Santarelli L: Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers (Basel); 2010;2(2):523-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.
  • Malignant mesothelioma (MM) is a rare and aggressive tumour of the serosal cavities linked to asbestos exposure.
  • Recently, some blood biomarkers have been described as potential indicators of early and advanced MM cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24281081.001).
  • [ISSN] 2072-6694
  • [Journal-full-title] Cancers
  • [ISO-abbreviation] Cancers (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3835090
  •  go-up   go-down


5. Srivastava V, Dunning J, Au J: Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis? Interact Cardiovasc Thorac Surg; 2009 Apr;8(4):454-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis?
  • The question addressed was: Does video-assisted thoracoscopic (VATS) decortication in advanced malignant mesothelioma improve prognosis?
  • We conclude that VATS decortication is useful as a palliative measure in advanced malignant mesothelioma.
  • [MeSH-major] Drainage. Mesothelioma / surgery. Pleural Neoplasms / surgery. Thoracic Surgery, Video-Assisted
  • [MeSH-minor] Aged. Benchmarking. Biopsy. Evidence-Based Medicine. Humans. Palliative Care. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / surgery. Predictive Value of Tests. Quality of Life. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136533.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 6
  •  go-up   go-down


6. Martin M: Clinical Experience With Pemetrexed in Breast Cancer. Semin Oncol; 2006 Feb;33 Suppl 2:15-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed possesses antitumor activity in several solid tumors, including non-small cell lung cancer, malignant pleural mesothelioma, pancreas, colorectal, gastric, bladder, breast, and head and neck cancers.
  • Pemetrexed has been tested in five phase II trials in locally advanced or metastatic breast cancer.
  • The drug has shown an activity of around 30% in advanced breast cancer patients with minimal or no prior chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140044.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Halstead JC, Lim E, Venkateswaran RM, Charman SC, Goddard M, Ritchie AJ: Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur J Surg Oncol; 2005 Apr;31(3):314-20
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
  • AIMS: Malignant mesothelioma is increasing in incidence and no current therapy significantly prolongs survival.
  • We present the results of VATS debulking pleurectomy-decortication in advanced disease.
  • METHODS: A consecutive series of patients with suspected malignant mesothelioma underwent thoracoscopic assessment to determine the feasibility of decortication, where this was not possible a biopsy alone was taken.
  • The two groups (biopsy only and pleurectomy-decortication) were composed of patients with histologically confirmed mesothelioma [28 and 51 patients, respectively].
  • CONCLUSION: VATS pleurectomy-decortication is feasible in the majority of cases and independently improves survival for patients with advanced malignant mesothelioma.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780570.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol; 2006 Jul;1(6):591-601
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
  • BACKGROUND: This clinical practice guideline, based on a systematic review, was developed to determine which chemotherapeutic agents (or combinations of agents) show the highest response rates, improved survival, quality of life, or symptom control in patients with advanced malignant pleural mesothelioma.
  • CONCLUSIONS: There is good evidence to recommend chemotherapy with pemetrexed and cisplatin for adult patients with symptomatic advanced malignant pleural mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mesothelioma / drug therapy. Mesothelioma / mortality. Pleural Neoplasms / drug therapy. Pleural Neoplasms / mortality. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409924.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Practice Guideline; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 0 / Quinazolines; 0 / Thiophenes; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; FCB9EGG971 / raltitrexed; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 133
  •  go-up   go-down


9. Gibbins J, Steeds C, Greenslade GL, Tunstall SR, Patel NK, Stannard CF: To replace or not to replace? - Partial coning and a sixth nerve palsy secondary due to displacement of a tunnelled intrathecal catheter for pain control. Palliat Med; 2008 Jul;22(5):668-70
Genetic Alliance. consumer health - Sixth nerve palsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient had advanced malignant mesothelioma and all other methods of pain control had been unsuccessful.
  • [MeSH-minor] Abducens Nerve Diseases / etiology. Cerebrospinal Fluid. Humans. Infusion Pumps, Implantable. Male. Mesothelioma / complications. Middle Aged. Pain, Intractable / drug therapy. Peritoneal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18612034.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Berrill J, Haboubi H, Duane P: Peritoneal mesothelioma. Br J Hosp Med (Lond); 2010 May;71(5):290-1
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal mesothelioma.
  • Peritoneal disease accounts for just under a third of all malignant mesothelioma.
  • Its insidious onset means that diagnosis is often made at an advanced stage, however, new therapeutic techniques are starting to lead to improved outcomes.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20448500.001).
  • [ISSN] 1750-8460
  • [Journal-full-title] British journal of hospital medicine (London, England : 2005)
  • [ISO-abbreviation] Br J Hosp Med (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mineral Fibers; 1332-21-4 / Asbestos
  •  go-up   go-down


11. Takeuchi K, Fujimoto M, Tsujino T, Takeda Y, Yoshida S: Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel. Eur J Gynaecol Oncol; 2007;28(4):322-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel.
  • BACKGROUND: The results of treatment of malignant peritoneal mesothelioma are quite unsatisfactory, especially in the later stages of the disease, regardless of the treatment modality employed.
  • CASE: We report a case of locally advanced malignant peritoneal mesothelioma, in which the combination of radiotherapy and intraperitoneal paclitaxel was beneficial for long-term disease stabilization.
  • The histologic study showed malignant peritoneal mesothelioma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Mesothelioma. Paclitaxel / administration & dosage. Peritoneal Neoplasms

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713104.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Porta C, Ardizzoni A, Gaudino G, Maio M, Mutti L, Pinto C, Porru S, Puntoni R, Tassi G, Tognon M: Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group. Med Lav; 2005 Jul-Aug;96(4):360-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group.
  • Malignant mesothelioma (MMe) is a seemingly uncommon tumour whose incidence has in fact increased steadily and progressively over the last 30 years.
  • To foster discussion among investigators working in this field, and to exchange different viewpoints concerning the newest advances in MMe pathogenesis and treatment, the VII International Mesothelioma Interest Group (IMIG) meeting was held in Brescia (Italy) between 24 and 26 June 2004 in cooperation with the Italian Group for the Study and Therapy of MMe (GIMe).
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Polyomavirus Infections / therapy. Tumor Virus Infections / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457433.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Carcinogens; 0 / Cytokines; 0 / Protease Inhibitors; 0 / Protein Kinase Inhibitors; 1332-21-4 / Asbestos
  •  go-up   go-down


13. Scagliotti GV, Selvaggi G: Emerging drugs for mesothelioma. Expert Opin Emerg Drugs; 2007 Mar;12(1):127-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for mesothelioma.
  • Malignant mesothelioma is an aggressive, but relatively rare, malignancy, affecting the pleura and peritoneum.
  • The prognosis for malignant pleural mesothelioma (MPM) is poor, with median survival in the range of 8-14 months, depending on stage and presentation of disease.
  • In advanced disease not amenable to any local approach, such as surgery, combination chemotherapy represents the current standard of care.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Pleural Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355218.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


14. Lisowska A, Knapp M, Sobkowicz B, Musiał WJ: [Severe right-ventricular heart failure due to malignant pericardial mesothelioma]. Kardiol Pol; 2005 Nov;63(5):569-70
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe right-ventricular heart failure due to malignant pericardial mesothelioma].
  • A case of a 63-year old female with symptomatic advanced right-ventricular (RV) heart failure due to malignant pericardial mesothelioma is presented.
  • Echocardiography revealed that RV failure was due to the tumour-induced compression of the right atrium and not due to metastatic mesothelioma involving pericardial sac.
  • [MeSH-major] Heart Neoplasms / complications. Mesothelioma / complications. Myocardial Infarction / etiology. Pericardium / pathology. Ventricular Dysfunction, Right / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362865.001).
  • [ISSN] 0022-9032
  • [Journal-full-title] Kardiologia polska
  • [ISO-abbreviation] Kardiol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


15. Gregorc V, Ceresoli GL, Zucali PA, De Braud FG, Bajetta E, Santoro A, Viganò MG, Caligaris-Cappio F, Lambiase A, Bordignon C: Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM). J Clin Oncol; 2009 May 20;27(15_suppl):7582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM).
  • METHODS: Patients with advanced MPM were treated with a low-dose of NGR-hTNF given intravenously at 0.8 μg/m<sup>2</sup> as 1-hour infusion every 3 weeks (q3w).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963379.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Dowell J, Taub R, Lan C, Xie Y, Dunphy F, Blake V, Kindler H: A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM). J Clin Oncol; 2009 May 20;27(15_suppl):7578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM).
  • CONCLUSIONS: These data suggest that the addition of B to PC does not improve PFS when compared with historical controls of PC in advanced MM pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963386.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hida T, Ogawa S, Park J, Park J, Shimizu J, Horio Y, Yoshida K, Sekido Y: Chemosensitivity of newly established human malignant pleural mesothelioma cells: Significant growth inhibition by amrubicin, a novel 9-aminoanthracycline, or cyclooxygenase 2 inhibitor. J Clin Oncol; 2009 May 20;27(15_suppl):e19060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensitivity of newly established human malignant pleural mesothelioma cells: Significant growth inhibition by amrubicin, a novel 9-aminoanthracycline, or cyclooxygenase 2 inhibitor.
  • : e19060 Background: Malignant pleural mesothelioma is asbestos-related malignancy that is highly resistant to current therapeutic modalities.
  • Survival of patients with malignant mesothelioma is very poor, especially in advanced stage, regardless of a recent advancement of chemotherapeutical modalities of combination with cisplatin and antifolate.
  • METHODS: Eleven cell lines derived from malignant mesothelioma were established in our laboratory.
  • RESULTS: Anti-cancer agents, cisplatin, vinorelbine, gemcitabine, gefitinib, or erlotinib, showed little growth inhibition, and pemetrexed and irinotecan showed modest growth inhibition in malignant mesothelioma cells, whereas amrubicin-13-OH showed strong growth inhibition.
  • Cyclooxygenase 2 inhibitors inhibit proliferation of malignant mesothelioma cells in a dose-dependent manner: modest growth inhibition at clinically achievable low concentrations and complete growth inhibition at clinically achievable high concentrations by intrapleural instillation.
  • CONCLUSIONS: Our study suggests that amrubicin can inhibit proliferation of malignant mesothelioma cells.
  • In addition, the use of a cyclooxygenase 2 inhibitor may be a promising therapeutic approach in the treatment of mesothelioma, because previous studies indicated the presence of increased cyclooxygenase 2 expression in malignant mesothelioma, which is notoriously resistant to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962139.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Yamaoka N, Kawasaki Y, Xu Y, Yamamoto H, Terada N, Okamura H, Kubo S: Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma. Int J Oncol; 2010 Aug;37(2):273-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma.
  • Malignant mesothelioma is a highly aggressive tumor with poor prognosis, and new treatment paradigms are urgently needed.
  • We developed in vivo fluorescence imaging models for human malignant mesothelioma in mice using tumor cells engineered to express fluorescent proteins (EGFP, mRFP, mCherry, and mPlum) by lentiviral vectors.
  • In both, peritoneally disseminated and orthotopic pleural mesothelioma models, mCherry-positive tumors were sensitively detected and tumor growth was successfully monitored.
  • This represents the first study to achieve sensitive tumor detection and tracking of tumor growth and development in the malignant mesothelioma mouse models by non-invasive in vivo fluorescence imaging.
  • These imaging models can be versatile and powerful tools to explore new treatment paradigms for malignant mesothelioma.
  • [MeSH-major] Diagnostic Imaging / methods. Disease Models, Animal. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596654.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Fluorescent Dyes
  •  go-up   go-down


19. Picklesimer AH, Zanagnolo V, Niemann TH, Eaton LA, Copeland LJ: Case report: malignant peritoneal mesothelioma in two siblings. Gynecol Oncol; 2005 Nov;99(2):512-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: malignant peritoneal mesothelioma in two siblings.
  • BACKGROUND: Mesothelioma is a rare tumor, linked with occupational asbestos exposure.
  • CASE: Our patient's brother was diagnosed with advanced stage malignant peritoneal mesothelioma in August 1995 at age of 42, he underwent tumor-reductive surgery followed by chemotherapy.
  • Our patient underwent cytoreductive surgery in May 1999 at age of 49 for advanced stage malignant peritoneal mesothelioma with suboptimal debulking.
  • CONCLUSION: This is the first report of two siblings of different gender with malignant peritoneal mesothelioma and only average environmental asbestos exposure.
  • [MeSH-major] Mesothelioma / genetics. Peritoneal Neoplasms / genetics

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051325.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Reck M, Heigener DF, Gatzemeier U: [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]. Zentralbl Chir; 2008 Jun;133(3):238-42
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
  • Chemotherapy of malignant mesothelioma is of great importance because most patients with malignant pleural mesothelioma are diagnosed for the first time with widespread or advanced disease.
  • After the introduction of modern antifolates in the chemotherapy for malignant mesothelioma and after the establishment of standardised response criteria, a significant prolongation of survival time by combination chemotherapy was shown in two randomised phase III trials.
  • The combination of pemetrexed and cisplatin is the current standard of chemotherapy in malignant mesothelioma.
  • In spite of the various results of preclinical trials which support the prognostic significance of certain targeted structures of intra- and intercellular signal transduction, no relevant efficacy could be shown for targeted therapies in mesothelioma up to now.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18563688.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glutamates; 0 / Quinazolines; 0 / Thiophenes; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; FCB9EGG971 / raltitrexed; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 29
  •  go-up   go-down


21. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C: Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol; 2008 Apr 1;26(10):1698-704
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
  • PURPOSE: This multicenter, phase III study compared overall survival (OS) of second-line pemetrexed plus best supportive care (BSC) versus BSC alone in patients with advanced malignant pleural mesothelioma (MPM).
  • CONCLUSION: Second-line pemetrexed elicited significant tumor response and delayed disease progression compared with BSC alone in patients with advanced MPM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Nov 1;26(31):5139-40 [18838696.001]
  • (PMID = 18375898.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


22. Ceresoli GL, Gridelli C, Santoro A: Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist; 2007 Jul;12(7):850-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary treatment of malignant pleural mesothelioma.
  • The incidence of malignant pleural mesothelioma (MPM) is increasing worldwide, and is predicted to peak in the next 10-20 years.
  • Further studies are needed to provide evidence-based recommendations for the treatment of early and advanced stages of this disease.
  • [MeSH-major] Combined Modality Therapy / methods. Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673616.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 134
  •  go-up   go-down


23. Amati M, Tomasetti M, Scartozzi M, Mariotti L, Ciuccarelli M, Valentino M, Governa M, Santarelli L: [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma]. G Ital Med Lav Ergon; 2007 Jul-Sep;29(3 Suppl):335-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
  • [Transliterated title] Utilizzo di biomarkers nella prevenzione e diagnosi precoce del Mesotelioma Maligno della pleura.
  • Improved detection methods for diagnosis of asymptomatic malignant pleural mesothelioma (MPM) are essential for an early and reliable detection and treatment of this disease.
  • The combination of 80HdG, VEGFbeta and SMRPs best distinguished the individual groups, suggesting a potential indicator of early and advanced MPM cancers.
  • The combination of blood biomarkers and radiographic findings could be used to stratify the risk of mesothelioma in asbestos-exposed populations.
  • [MeSH-major] Biomarkers, Tumor / blood. Mesothelioma / diagnosis. Mesothelioma / prevention & control. Pleural Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409713.001).
  • [ISSN] 1592-7830
  • [Journal-full-title] Giornale italiano di medicina del lavoro ed ergonomia
  • [ISO-abbreviation] G Ital Med Lav Ergon
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Sugarbaker DJ, Wolf AS: Surgery for malignant pleural mesothelioma. Expert Rev Respir Med; 2010 Jun;4(3):363-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for malignant pleural mesothelioma.
  • The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding of this rare and aggressive malignancy.
  • The former is indicated for patients with advanced locally invasive disease; the latter for patients with more superficial spread of tumor that spares the lung and fissures.
  • Despite having more advanced disease, a subset of patients with favorable prognostic factors can experience extended survival by undergoing trimodality therapy with extrapleural pneumonectomy, chemotherapy and/or radiation.
  • Much of what we know about the biology of mesothelioma has been gleaned from studying the surgical pathophysiology, including the delineation of histopathologic subtypes, disease stage stratification with survival, the propensity for local (in contrast to systemic) recurrence, as well as the prognostic effect of epithelial versus nonepithelial cell type, extrapleural nodal involvement, tumor bulk and surgical margins.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Thoracic Surgical Procedures

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524919.001).
  • [ISSN] 1747-6356
  • [Journal-full-title] Expert review of respiratory medicine
  • [ISO-abbreviation] Expert Rev Respir Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


25. Tanida S, Kataoka H, Kubota E, Mori Y, Sasaki M, Ogasawara N, Wada T, Mizoshita T, Shimura T, Murakami K, Mizushima T, Hirata Y, Okamoto Y, Mabuchi M, Ebi M, Tanaka M, Kamiya T, Takahashi S, Joh T: Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. Int J Clin Oncol; 2009 Jun;14(3):266-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma.
  • Malignant peritoneal mesothelioma is a rare neoplasm with a rapidly fatal course.
  • The response of this disease to treatment is poor because it tends to be advanced at diagnosis and tends to have inherent resistance to chemotherapeutic treatment.
  • We describe three patients with malignant peritoneal mesothelioma who received combination chemotherapy with cisplatin and gemcitabine.
  • After a histopathological diagnosis of epithelial-type malignant peritoneal mesothelioma, all patients underwent systemic chemotherapy because of the advanced disease stage.
  • Combination chemotherapy with cisplatin and gemcitabine may prove to be one of the recommended treatments for patients with malignant peritoneal mesothelioma in the near future.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Thorac Surg Clin. 2004 Nov;14(4):469-77, viii [15559053.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Crit Rev Diagn Imaging. 1985;24(4):293-328 [3896651.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2375-84 [10357408.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Br J Ind Med. 1964 Jan;21:20-31 [14106131.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):342-5 [11875695.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):56-7 [12903546.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi [14567020.001]
  • [Cites] Arch Surg. 1988 Jun;123(6):763-6 [2453184.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):491-6 [12189542.001]
  • (PMID = 19593622.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Matsuzaki Y, Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T: Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma. Ann Thorac Cardiovasc Surg; 2008 Jun;14(3):161-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
  • PURPOSE: Despite extensive clinical research, no effective therapy for advanced malignant pleural mesothelioma has been established.
  • MATERIAL AND METHODS: Our study included 6 consecutive patients with malignant pleural mesothelioma (stage III: 5; stage IV: 1).
  • Because of the advanced stage of the disease, none of the patients underwent tumor resection or pleurectomy.
  • CONCLUSION: In patients with malignant pleural mesothelioma, intrapleural perfusion hyperthermo-chemotherapy induced potent apoptosis of tumor cells, increasing immediately postperfusion and peaking at 24 h.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Cisplatin / therapeutic use. Hyperthermia, Induced. Mesothelioma / therapy. Perfusion. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pleural Effusion, Malignant / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577894.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Rezaei Kalantari H: [Malignant peritoneal mesothelioma: a case report]. Rev Med Liege; 2010 Sep;65(9):490-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma: a case report].
  • [Transliterated title] Le cas clinique du mois. Mésothéliome péritonéal malin.
  • I report two cases of malignant peritoneal mesothelioma.
  • Mesothelioma is mostly a pleural disease whether visceral or parietal.
  • Infra-diaphragmatic Mesothelioma accounts for only 10-20% of all mesotheliomas.
  • Sadly the disease is often unveiled at an advanced stage requiring palliative chemotherapy usually with a platin derivative or in a small percentage of the cases with abdominal radiotherapy to alleviate pain.
  • Prognosis for patients with malignant peritoneal mesothelioma is very poor with a mean survival of 5,4 months versus 12.5 months for pleural mesothelioma.
  • Peritoneal mesothelioma, although rare, should be considered among the differential diagnosis of ascites differential diagnosis work up.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086578.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


28. Parente B: Mesothelioma treatment. Rev Port Pneumol; 2008 Jul;14 Suppl 2:S35-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma treatment.
  • [Transliterated title] Terapêutica do mesotelioma.
  • Malignant mesothelioma (MM) is a locally aggressive advanced tumour, with bad prognosis and many times fatal, who have been growing in the last two decades with possibilities to be continue in all the world until 2020, showing use of pic asbestos to the years 1960/1970.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 Sociedade Portuguesa de Pneumologia/SPP.
  • (PMID = 25967566.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Malignant pleural mesothelioma / Mesotelioma pleural maligno / chemotherapy / pemetrexed / quimioterapia / tratamento / treatment
  •  go-up   go-down


29. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • Radical surgery can be used to treat localized mesothelioma.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 16
  •  go-up   go-down


30. Rice DC, Erasmus JJ, Stevens CW, Vaporciyan AA, Wu JS, Tsao AS, Walsh GL, Swisher SG, Hofstetter WL, Ordonez NG, Smythe WR: Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg; 2005 Dec;80(6):1988-92; discussion 1992-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended surgical staging for potentially resectable malignant pleural mesothelioma.
  • BACKGROUND: Extrapleural pneumonectomy for malignant pleural mesothelioma (MPM) is a high-risk procedure, and patients require careful preoperative staging to exclude advanced disease.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / surgery. Neoplasm Staging / methods. Pleural Neoplasms / pathology. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Dec;82(6):2337; author reply 2337-8 [17126172.001]
  • (PMID = 16305830.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


31. Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, Abdel-Hamid A, Eldin NA, Mokhtar N: Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer; 2010 Oct;70(1):43-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an asbestos related aggressive tumor.
  • Elevated serum and tissue EGFR is significantly associated with advanced disease stage.
  • High pre-treatment levels of serum EGFR are associated with advanced stage but not with reduced OS.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Mesothelioma / enzymology. Pleural Neoplasms / enzymology. Receptor, Epidermal Growth Factor / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20347505.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


32. Tamura E, Kozaki M, Kunimoto M, Tokuyama S, Kawanami Y, Watanabe H, Hamada T, Morooka M, Mukae H: [A case of localized malignant pleural mesothelioma]. Nihon Kokyuki Gakkai Zasshi; 2010 Jul;48(7):511-5
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of localized malignant pleural mesothelioma].
  • Chemotherapy was initiated for advanced-stage lung cancer, but was not effective.
  • Histopathologic and immunohistochemical examinations after CT-guided needle biopsy revealed malignant mesothelioma.
  • This is a rare and important case of localized malignant mesothelioma pathologically confirmed by biopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684215.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ: Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol; 2006 Jan;1(1):25-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
  • PURPOSE: To investigate the toxicity and effectiveness of pemetrexed maintenance therapy (PMT) in patients with malignant pleural mesothelioma (MPM).
  • PATIENTS AND METHODS: Eligible were patients with histologically proven advanced MPM, WHO PS 0-2 and adequate hematological, renal and hepatic function in whom during 6 courses of pemetrexed containing induction therapy no disease progression was observed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409823.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


34. Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR: Malignant pleural mesothelioma: a comprehensive review. Cancer Control; 2006 Oct;13(4):255-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: a comprehensive review.
  • BACKGROUND: The incidence of malignant mesothelioma continues to increase, but the disease remains difficult to detect early and treat effectively.
  • METHODS: The authors review the pathogenesis, incidence, clinical presentation, diagnosis, pathology, and both standard and experimental treatments for mesothelioma.
  • In patients with advanced disease, several newer antitumor agents are already showing a capability of extending survival so it is not unreasonable to expect further progress in this area.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Pleural Neoplasms / diagnosis. Pleural Neoplasms / therapy
  • [MeSH-minor] Humans. Incidence. Magnetic Resonance Imaging. Neoplasm Staging. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / therapy. Tomography, X-Ray Computed. United States / epidemiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075562.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


35. Patel SN, Kettner NW: Malignant pleural mesothelioma: a case report. J Manipulative Physiol Ther; 2005 Nov-Dec;28(9):724-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: a case report.
  • OBJECTIVE: The aim of this study was to discuss a case of malignant pleural mesothelioma (MPM) that presented to a chiropractic teaching clinic and review the pathophysiology of diseases associated with asbestos exposure.
  • An extrapleural pneumonectomy was performed, and specimens of parietal and visceral pleura were sent for pathological, which revealed a definitive diagnosis of spindle cell mesothelioma.
  • INTERVENTION AND OUTCOME: The patient was diagnosed with MPM, and a surgical therapy option was considered because of the aggressive nature of the lesion and her advanced age.
  • CONCLUSION: This is an unusual case of advanced MPM that is most likely from indirect asbestos exposure.
  • [MeSH-major] Mesothelioma / physiopathology. Pleural Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326244.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


36. Bahrami A, Allen TC, Cagle PT: Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma. Pathol Int; 2008 Nov;58(11):730-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
  • The patient underwent thoracotomy and was found to have a locally advanced, surgically unresectable lung tumor, involving the pleura, pericardium and diaphragm.
  • Histologically the tumor had an epithelioid and spindled appearance, without high-grade histological features, and was initially thought to represent biphasic diffuse malignant mesothelioma.
  • Mesothelioma markers were universally negative and cytokeratin was focally reactive only in some epithelioid cells.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / diagnosis. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844940.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Azim HA Jr, Gaafar R, Abdel Salam I, El-Guindy S, Elattar I, Ashmawy A, Khorshid O: Soluble mesothelin-related protein in malignant pleural mesothelioma. J Egypt Natl Canc Inst; 2008 Sep;20(3):224-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related protein in malignant pleural mesothelioma.
  • BACKGROUND AND PURPOSE: Building-up evidence suggests that soluble mesothelinrelated protein (SMRP) carries a diagnostic and a prognostic value in malignant pleural mesothelioma (MPM).
  • The mean SMRP concentrations were significantly higher in patients with advanced disease (p = 0.038), poor performance status (p = 0.017) and high alkaline phosphatase (p = 0.015).
  • KEY WORDS: Malignant pleural mesothelioma (MPM) - Soluble mesothelin related protein (SMRP)- Sensitivity - Specificity - Asbestos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20424652.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


38. Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, Groshen S, Laird PW, Turla S, Koss MN, Pass HI, Laird-Offringa IA: DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer; 2007 Nov;58(2):220-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation profile of 28 potential marker loci in malignant mesothelioma.
  • Patients with malignant mesothelioma (MM), an aggressive cancer associated with asbestos exposure, usually present clinically with advanced disease and this greatly reduces the likelihood of curative treatment.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3080-97 [12912960.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4128-33 [12821947.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):786-92 [14999791.001]
  • [Cites] Occup Environ Med. 2004 May;61(5):438-41 [15090665.001]
  • [Cites] Environ Health Perspect. 2004 May;112(6):731-9 [15121517.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6672-6 [15221014.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):361-71 [15488759.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1087-92 [15492797.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1172-8 [8501504.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2570-6 [10375104.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):150-7 [10395284.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):600-4 [15472908.001]
  • [Cites] Lung Cancer. 2005 Feb;47(2):193-204 [15639718.001]
  • [Cites] Occup Environ Med. 2005 Feb;62(2):134 [15657198.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1302-8 [15592515.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R65-76 [15809275.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:629-56 [15822191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1274-8 [15894685.001]
  • [Cites] Hum Pathol. 2005 May;36(5):465-73 [15948112.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S109-11 [15950789.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S3-8 [15950797.001]
  • [Cites] Respirology. 2005 Jun;10(3):266-83 [15955137.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):6823-36 [16326863.001]
  • [Cites] Mol Cancer. 2005;4:42 [16351731.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 21;342(4):1228-32 [16516163.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1300-16 [16329111.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):656-67 [16575877.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):723-34 [16795078.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31 [16857795.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):109-16 [16893590.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10621-9 [17079487.001]
  • [Cites] Dis Markers. 2007;23(1-2):5-30 [17325423.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Curr Opin Pulm Med. 2000 Mar;6(2):157-63 [10741777.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;249:101-18 [10802941.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4556-60 [11389090.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5727-30 [11479207.001]
  • [Cites] Methods. 2001 Dec;25(4):456-62 [11846615.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1127-30 [12117769.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4963-7 [12208747.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):131-6 [12399123.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:827-30 [12426140.001]
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):127-30 [12601276.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):735-44 [12640681.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):849-59 [14871960.001]
  • (PMID = 17659810.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA014089-349012; United States / NCI NIH HHS / CA / P30 CA014089; United States / NCI NIH HHS / CA / P30 CA 14089; United States / NCI NIH HHS / CA / P30 CA014089-349012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS33001; NLM/ PMC2752414
  •  go-up   go-down


39. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol; 2006 May;1(4):289-95
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
  • INTRODUCTION: Extrapleural pneumonectomy (EPP) and adjuvant high-dose radiation therapy (RT) are associated with a median survival of 3 years in early-stage malignant pleural mesothelioma (MPM) but of less than 1 year in locally advanced disease.
  • We designed this clinical trial to test the feasibility of induction chemotherapy followed by EPP and RT in locally advanced MPM with the ultimate aim of improving survival.
  • CONCLUSION: Induction chemotherapy with gemcitabine and cisplatin followed by EPP and adjuvant RT for locally advanced MPM is feasible and leads to a better median overall survival than that previously reported with EPP and RT alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pneumonectomy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409872.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Kubo S, Kawasaki Y, Yamaoka N, Tagawa M, Kasahara N, Terada N, Okamura H: Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus. J Gene Med; 2010 Aug;12(8):681-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus.
  • BACKGROUND: Malignant mesothelioma is a highly aggressive tumor with poor prognosis.
  • We hypothesized that the tumor-specific midkine (Mdk) promoter could confer transcriptional targeting to oncolytic adenoviruses for effective treatment of malignant mesothelioma.
  • METHODS: We analysed Mdk expression by quantitative reverse transcription-polymerase chain reaction in six human mesothelioma cell lines, and tested Mdk promoter activity by luciferase reporter assay.
  • Selectivity of viral replication and cytolysis were characterized in normal versus mesothelioma cells in vitro, and intratumoral spread and antitumor efficacy were investigated in vivo.
  • RESULTS: Mdk promoter activity was restricted in normal cells, but highly activated in mesothelioma cell lines.
  • AdMdk-E1-iresTK was seen to efficiently replicate, produce viral progeny and spread in multiple mesothelioma cell lines.
  • Lytic spread of AdMdk-E1-iresTK mediated the efficient killing of these mesothelioma cells, and its in vitro cytocidal effect was significantly enhanced by treatment with the prodrug, ganciclovir.
  • Intratumoral injection of AdMdk-E1-iresTK caused complete regression of MESO4 and MSTO human mesothelioma xenografts in athymic mice.
  • CONCLUSIONS: These data indicate that transcriptional targeting of viral replication by the Mdk promoter represents a promising general strategy for oncolytic virotherapy of cancers with up-regulated Mdk expression, including malignant mesothelioma.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 John Wiley & Sons, Ltd.
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7120-9 [18757427.001]
  • [Cites] Gene Ther. 2008 Jun;15(12):877-84 [18418413.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2081-90 [19255316.001]
  • [Cites] J Neurochem. 1999 Nov;73(5):2084-92 [10537068.001]
  • [Cites] J Biochem. 2000 Feb;127(2):269-77 [10731694.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):848-52 [10835519.001]
  • [Cites] Nat Biotechnol. 2000 Jul;18(7):723-7 [10888838.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):97-105 [11244508.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8743-50 [11751394.001]
  • [Cites] Clin Chest Med. 2002 Mar;23(1):265-77 [11901916.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8366-76 [14678998.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):127-43 [15013213.001]
  • [Cites] J Gen Virol. 1977 Jul;36(1):59-74 [886304.001]
  • [Cites] Science. 1990 Dec 21;250(4988):1690-4 [2270483.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Jun 14;177(2):652-8 [2049087.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1281-5 [8383007.001]
  • [Cites] Am J Respir Cell Mol Biol. 1993 Nov;9(5):463-6 [8217186.001]
  • [Cites] Cancer. 1994 Sep 1;74(5):1584-90 [7520350.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):655-61 [7559083.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Nov 13;216(2):574-81 [7488150.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Feb 6;219(1):256-60 [8619817.001]
  • [Cites] Br J Cancer. 1997;75(3):354-9 [9020479.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1814-9 [9135027.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):410-3 [9927055.001]
  • [Cites] Hum Gene Ther. 1999 Mar 1;10(4):649-57 [10094208.001]
  • [Cites] Jpn J Cancer Res. 1999 Apr;90(4):469-75 [10363587.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1039-49 [16050782.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7444-53 [16243818.001]
  • [Cites] Mol Ther. 2006 Feb;13(2):347-56 [16290236.001]
  • [Cites] Cancer Biol Ther. 2006 Jan;5(1):48-53 [16294031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 23;103(21):8036-41 [16698926.001]
  • [Cites] Cancer Gene Ther. 2006 Oct;13(10):897-904 [16439992.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):255-63 [17075562.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):701-11 [17409940.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):405-11 [17622248.001]
  • [Cites] Pediatr Surg Int. 2008 Dec;24(12):1355-9 [18956201.001]
  • (PMID = 20635326.001).
  • [ISSN] 1521-2254
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA016042-355669; United States / NIDDK NIH HHS / DK / DK041301-209011; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIDDK NIH HHS / DK / P30 DK041301-209011; United States / NIDDK NIH HHS / DK / P30 DK041301; United States / NCI NIH HHS / CA / P30 CA016042-355669
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 137497-38-2 / midkine; EC 2.7.1.21 / Thymidine Kinase
  • [Other-IDs] NLM/ NIHMS228969; NLM/ PMC2938764
  •  go-up   go-down


41. Gupta V, Krug LM, Laser B, Hudka K, Flores R, Rusch VW, Rosenzweig KE: Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol; 2009 Jun;4(6):746-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.
  • INTRODUCTION: Multimodality therapy including extrapleural pneumonectomy (EPP), chemotherapy, and radiotherapy (RT) is often recommended for fit patients with early stage malignant pleural mesothelioma.
  • We studied patterns of local and nodal recurrence in patients treated at our institution with EPP and RT, and whether advanced treatment planning techniques, such as intensity modulated radiotherapy (IMRT), could have been of potential benefit.
  • METHODS: From 1993 to 2008, 86 patients with malignant pleural mesothelioma underwent EPP followed by hemithoracic RT (median dose: 54 Gy).
  • [MeSH-major] Mesothelioma / radiotherapy. Mesothelioma / surgery. Neoplasm Recurrence, Local / pathology. Photons. Pleural Neoplasms / radiotherapy. Pleural Neoplasms / surgery. Pneumonectomy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404212.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B: Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch; 2006 Jul;449(1):31-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.
  • The aim of the present study was to evaluate HLA-G expression in breast carcinoma and malignant mesothelioma (MM).
  • Malignant breast carcinoma effusions (46) and corresponding solid tumors (39) and 104 MM (26 effusions, 78 solid tumors) were analyzed using immunohistochemistry (IHC).
  • However, the up-regulated expression of HLA-G in MM effusions and its possible association with shorter disease-free survival in advanced stage of breast carcinoma suggest a possible role in immune response evasion in some tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis. Mesothelioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / immunology. Ascitic Fluid / pathology. Biopsy. Female. Gene Expression. HLA-G Antigens. Humans. Male. Middle Aged. Pleural Effusion, Malignant / immunology. Pleural Effusion, Malignant / pathology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):914-20 [12131159.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Acta Cytol. 1994 Nov-Dec;38(6):945-52 [7992584.001]
  • [Cites] Blood. 2002 Jan 15;99(2):609-17 [11781245.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1515-23 [12438449.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):18-25 [11836665.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(2):119-28 [14997042.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1954-60 [10213506.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):5922-8 [9637505.001]
  • [Cites] Respiration. 1998;65(2):108-13 [9580921.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6838-45 [11559559.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):243-50 [14639610.001]
  • [Cites] Eur J Surg Oncol. 1994 Feb;20(1):33-6 [8131866.001]
  • [Cites] Hum Immunol. 2005 Feb;66(2):164-9 [15695002.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1081-92 [14602239.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):512-8 [10225437.001]
  • [Cites] J Immunol Methods. 2002 Jun 1;264(1-2):109-19 [12191515.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):246-54 [15452897.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):42-7 [15589578.001]
  • [Cites] Clin Lab Med. 2003 Sep;23(3):729-54, viii [14560537.001]
  • [Cites] Microbes Infect. 2002 Dec;4(15):1539-44 [12505526.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):904-10 [15069585.001]
  • [Cites] Lung Cancer. 2004 May;44(2):159-65 [15084380.001]
  • [Cites] Semin Oncol. 1985 Mar;12(1):54-75 [2579439.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7335-46 [15534110.001]
  • [Cites] Placenta. 2000 Mar-Apr;21 Suppl A:S86-92 [10831130.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):43-9 [10431845.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7167-75 [14612510.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1177-95 [11137224.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4107-11 [12874014.001]
  • [Cites] Clin Exp Metastasis. 2004;21(5):469-76 [15672872.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23 ):5490-8 [8968106.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1377-87 [8620412.001]
  • [Cites] Hum Immunol. 2002 Nov;63(11):969-76 [12392849.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):317-23 [14708711.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1405-12 [11684957.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3771-8 [7706718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):85-92 [12109861.001]
  • (PMID = 16541284.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I; 0 / RNA, Messenger
  •  go-up   go-down


43. Neragi-Miandoab S, Richards WG, Sugarbaker DJ: Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg; 2008 Aug;6(4):293-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
  • AIM: The survival of patients with malignant pleural mesothelioma (MPM) who do not seek treatment ranges from 4 to 12 months.
  • To date, the optimal procedure for resection of malignant pleural mesothelioma is controversial, extrapleural pneumonectomy has been most consistently associated with long-term survival and has provided the most radical cytoreduction; but, unfortunately, not all patients qualify for this invasive surgical approach.
  • CONCLUSION: Our results show that pleurectomy can be performed as a means of palliation for advanced-stage disease with a low mortality rate and may, in fact, improve survival in patients with epithelial subtype as compared with historical controls in the literature with no surgical intervention.
  • [MeSH-major] Cause of Death. Mesothelioma / mortality. Mesothelioma / surgery. Pleural Neoplasms / mortality. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18585112.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Vogelzang NJ, Porta C, Mutti L: New agents in the management of advanced mesothelioma. Semin Oncol; 2005 Jun;32(3):336-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New agents in the management of advanced mesothelioma.
  • Malignant pleural mesothelioma (MPM) is a seemingly uncommon tumor whose incidence has in fact increased steadily and progressively over the last 30 years.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988688.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 0 / Proteasome Inhibitors; 0 / Ubiquitin; 0 / Vascular Endothelial Growth Factor A; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 3.1.- / Ribonucleases; EC 3.1.- / ranpirnase
  • [Number-of-references] 158
  •  go-up   go-down


45. Murdzhev K, Uchikov A, Iankulov A, Paskalev G: [Video-assisted thoracoscopic surgery in diagnostic and treatment of non-operable malignant pleural mesothelioma]. Khirurgiia (Sofiia); 2007;(4):23-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Video-assisted thoracoscopic surgery in diagnostic and treatment of non-operable malignant pleural mesothelioma].
  • INTRODUCTION: Mesothelioma is characterized by aggressive follow-up, difficult diagnosis and treatment fatal issue.
  • In one side the restricted possibility for operative treatment and the other side the resistance of tumors for chemotherapy are the mean reasons for bad results in patients with malignant pleural mesothelioma.
  • We have aim to make a retrospective study of patients with malignant pleural mesothelioma in 3-th and 4-th stage, undergoing operation in our clinic and see VATS effectiveness.
  • PATIENTS AND METHODS: In the clinic of thoracic surgery in University Hospital "St.George" - Plovdiv we made retrospective study in 21 patients undergoing operation in the occasion of advanced pleural mesothelioma.
  • DISCUSSION: Early diagnosis of malignant pleural mesothelioma is difficult, in some times impossible.
  • Surgical treatment is decisive for diagnosis and treatment of malignant pleural mesothelioma even in advanced cases and have evident positive effects.
  • 3. VATS surgery is modern method for diagnosis and treatment and if it necessary we can continue by conventional operation for definitive treatment of mesothelioma.
  • [MeSH-major] Mesothelioma. Pleural Neoplasms. Thoracic Surgery, Video-Assisted / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443531.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


46. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, Dang NH, Morimoto C: Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res; 2007 Jul 15;13(14):4191-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
  • In this report, we show that CD26 is highly expressed on the cell surface of malignant mesothelioma and that a newly developed humanized anti-CD26 monoclonal antibody (mAb) has an inhibitory effect on malignant mesothelioma cells in both in vitro and in vivo experiments.
  • EXPERIMENTAL DESIGN: Using immunohistochemistry, 12 patients' surgical specimens consisting of seven malignant mesothelioma, three reactive mesothelial cells, and two adenomatoid tumors were evaluated for expression of CD26.
  • The effects of CD26 on malignant mesothelioma cells were assessed in the presence of transfection of CD26-expressing plasmid, humanized anti-CD26 mAb, or small interfering RNA against CD26.
  • The in vivo growth inhibitory effect of humanized anti-CD26 mAb was assessed in human malignant mesothelioma cell mouse xenograft models.
  • RESULTS: In surgical specimens, CD26 is highly expressed in malignant mesothelioma but not in benign mesothelial tissues.
  • Moreover, our in vitro data indicate that humanized anti-CD26 mAb induces cell lysis of malignant mesothelioma cells via antibody-dependent cell-mediated cytotoxicity in addition to its direct anti-tumor effect via p27(kip1) accumulation.
  • In vivo experiments with mouse xenograft models involving human malignant mesothelioma cells show that humanized anti-CD26 mAb treatment drastically inhibits tumor growth in tumor-bearing mice, resulting in enhanced survival.
  • CONCLUSIONS: Our data strongly suggest that humanized anti-CD26 mAb treatment may have potential clinical use as a novel cancer therapeutic agent in CD26-positive malignant mesothelioma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Dipeptidyl Peptidase 4 / immunology. Lung Neoplasms / immunology. Mesothelioma / immunology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634548.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.4.14.5 / Dipeptidyl Peptidase 4
  •  go-up   go-down


47. Amati M, Tomasetti M, Scartozzi M, Mariotti L, Alleva R, Pignotti E, Borghi B, Valentino M, Governa M, Neuzil J, Santarelli L: Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev; 2008 Jan;17(1):163-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
  • Improved detection methods for diagnosis of asymptomatic malignant mesothelioma (MM) are essential for an early and reliable detection and treatment of this type of neoplastic disease.
  • The combination of 8OHdG, VEGFbeta, and SMRPs best distinguished the individual groups, suggesting a potential indicator of early and advanced MM cancers.
  • The combination of blood biomarkers and radiographic findings could be used to stratify the risk of mesothelioma in asbestos-exposed populations.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199721.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


48. Vural M, Abali H, Oksuzoglu B, Akbulut M: An atypical presentation of thymoma with diffuse pleural dissemination mimicking mesothelioma. Cancer Invest; 2006 Oct;24(6):615-20
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical presentation of thymoma with diffuse pleural dissemination mimicking mesothelioma.
  • Additionally, the radiological diagnosis of thymoma can be differentiated easily from malignant pleural mesothelioma in most cases.
  • Here, we report a case of advanced thymoma mimicking malignant pleural mesothelioma, with circumferential encasement of the lung.
  • [MeSH-major] Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Thymoma / diagnosis. Thymus Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982467.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Chen JL, Hsu YH: Malignant mesothelioma of the tunica vaginalis testis: a case report and literature review. Kaohsiung J Med Sci; 2009 Feb;25(2):77-81
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma of the tunica vaginalis testis: a case report and literature review.
  • Malignant mesothelioma of the tunica vaginalis testis is a rare but often fatal malignancy.
  • Here, we report one patient with locally advanced disease who has a history of asbestos exposure.
  • [MeSH-major] Mesothelioma / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Kaohsiung J Med Sci. 2014 Oct;30(10):537-8 [25438686.001]
  • (PMID = 19321410.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


50. Paik PK, Krug LM: Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol; 2010 Feb;5(2):275-9
Hazardous Substances Data Bank. Vorinostat .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
  • Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer of the mesothelium with only a limited range of treatment options that are largely ineffective in improving survival.
  • The results of these efforts have led to a multicenter, randomized, placebo-controlled phase III study of the histone deacetylase inhibitor vorinostat in patients with advanced MPM, offering hope for a new and effective therapy in patients with this disease.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Histone Deacetylase Inhibitors / pharmacology. Histone Deacetylase Inhibitors / therapeutic use. Hydroxamic Acids / pharmacology. Hydroxamic Acids / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Feb 10;24(7):1302-8 [15592515.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Nov;25(5):562-8 [11713097.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2586-96 [12239173.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):606-13 [12402037.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91 [14715264.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1813-25 [15014036.001]
  • [Cites] Prostate. 2004 May 1;59(2):177-89 [15042618.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6962-8 [15501975.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9 [2072706.001]
  • [Cites] Mech Dev. 1993 Jan;40(1-2):85-97 [8382938.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1781-90 [8183577.001]
  • [Cites] J Pathol. 1997 Jan;181(1):67-74 [9072005.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Feb;115(2):310-7; discussion 317-8 [9475525.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Chest Surg Clin N Am. 1999 May;9(2):327-38, x [10365266.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):391-400 [15765097.001]
  • [Cites] APMIS. 2005 Apr;113(4):264-8 [15865607.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1117-36, vii [16325127.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13548-58 [16533812.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98 [17428177.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3605-10 [17510206.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1196-202 [17429100.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2007 Dec;39(12):931-8 [18064385.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5777-84 [18089875.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] J Thorac Oncol. 2009 Jan;4(1):97-101 [19096314.001]
  • [Cites] J Thorac Oncol. 2009 Feb;4(2):149-60 [19179889.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Apr;18(4):501-8 [19335278.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2818-28 [19351772.001]
  • [Cites] Cancer Causes Control. 2009 Aug;20(6):935-44 [19294523.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1409-20 [19509247.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3007-13 [19364962.001]
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Jpn J Cancer Res. 2001 Dec;92(12):1300-4 [11749695.001]
  • (PMID = 20035240.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009207
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Number-of-references] 47
  • [Other-IDs] NLM/ NIHMS589324; NLM/ PMC4052955
  •  go-up   go-down


51. Adusumilli PS, Stiles BM, Chan MK, Mullerad M, Eisenberg DP, Ben-Porat L, Huq R, Rusch VW, Fong Y: Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med; 2006 May;8(5):603-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive cancer that is refractory to current treatment modalities.
  • Furthermore, NV1066 was able to reduce the tumor burden and prolong survival even when treatment was at an advanced stage of the disease.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Meso-10 (CVCL_H668) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Meso-9 (CVCL_H669) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 John Wiley & Sons, Ltd.
  • [Cites] J Gene Med. 2003 Aug;5(8):681-9 [12898637.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1261-5 [3861775.001]
  • [Cites] J Occup Med. 1983 May;25(5):409-25 [6854431.001]
  • [Cites] Surgery. 2003 Aug;134(2):357-64 [12947341.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1053-60 [3473246.001]
  • [Cites] J Infect Dis. 1988 Sep;158(3):602-14 [2842408.001]
  • [Cites] J Infect Dis. 1990 Aug;162(2):313-21 [2165104.001]
  • [Cites] Semin Surg Oncol. 1990;6(5):279-85 [2237087.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):1001-6 [1588364.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):373S-376S [8462328.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1209-15 [8040888.001]
  • [Cites] Ann Thorac Surg. 1995 Apr;59(4):835-44 [7695406.001]
  • [Cites] Nat Med. 1995 Sep;1(9):938-43 [7585221.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):466-71 [9012475.001]
  • [Cites] Am J Epidemiol. 1997 Feb 1;145(3):211-8 [9012593.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Gene Ther. 1998 Feb;5(2):160-5 [9578834.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):367-72 [9821167.001]
  • [Cites] Chest Surg Clin N Am. 1999 May;9(2):327-38, x [10365266.001]
  • [Cites] J Virol. 1999 Aug;73(8):6319-26 [10400723.001]
  • [Cites] Hum Gene Ther. 1999 Jul 1;10(10):1599-606 [10428205.001]
  • [Cites] FASEB J. 1999 Aug;13(11):1325-34 [10428757.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] Gene Ther. 2000 May;7(10):859-66 [10845724.001]
  • [Cites] Gene Ther. 2000 May;7(10):867-74 [10845725.001]
  • [Cites] J Mol Med (Berl). 2000;78(3):166-74 [10868479.001]
  • [Cites] Mol Ther. 2000 Dec;2(6):588-95 [11124059.001]
  • [Cites] World J Surg. 2001 Feb;25(2):210-7 [11338024.001]
  • [Cites] FASEB J. 2001 May;15(7):1306-8 [11344122.001]
  • [Cites] Ann Surg. 2001 Jun;233(6):819-26 [11371740.001]
  • [Cites] Hum Gene Ther. 2001 May 20;12(8):999-1010 [11387063.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Mol Med. 2001 Aug;7(8):561-8 [11591892.001]
  • [Cites] Gene Ther. 2002 Jan;9(1):75-80 [11850725.001]
  • [Cites] Hum Gene Ther. 2002 Jul 1;13(10):1213-23 [12133274.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):337-42; discussion 342-3 [12192320.001]
  • [Cites] Surgery. 2002 Aug;132(2):353-9 [12219034.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):95-100 [12242723.001]
  • [Cites] Cancer Gene Ther. 2002 Nov;9(11):935-45 [12386832.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:217-25 [12401694.001]
  • [Cites] Cancer Gene Ther. 2002 Dec;9(12):967-78 [12522436.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):167-74 [12610498.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2629-30 [12860935.001]
  • (PMID = 16475242.001).
  • [ISSN] 1099-498X
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075416; United States / NCI NIH HHS / CA / R01 CA080982; United States / NCI NIH HHS / CA / R01 CA 75416; United States / NCI NIH HHS / CA / R01 CA/DK 80982
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ NIHMS7189; NLM/ PMC1804293
  •  go-up   go-down


52. Maeda R, Isowa N, Onuma H, Miura H, Touge H, Kawasaki Y: Stage Ia malignant pleural mesothelioma: clinical course and appropriate diagnostic process. Gen Thorac Cardiovasc Surg; 2009 May;57(5):264-8
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage Ia malignant pleural mesothelioma: clinical course and appropriate diagnostic process.
  • Early-stage malignant pleural mesothelioma (MPM) is difficult for physicians to diagnose, and the disease is usually advanced at the time of diagnosis.
  • [MeSH-major] Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1241-5 [10450672.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):389-93 [8319170.001]
  • [Cites] Cancer. 1986 Oct 1;58(7):1540-51 [3742473.001]
  • [Cites] Cancer. 2000 Feb 25;90(1):55-60 [10692217.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):394-404 [8319171.001]
  • (PMID = 19440826.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Motta AB, Pinheiro G, Antonângelo L, Parra ER, Monteiro MM, Pereira JC, Takagaki T, Terra Filho M, Martins S, Capelozzi VL: Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases. J Bras Pneumol; 2006 Jul-Aug;32(4):322-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases.
  • OBJECTIVE: Various markers have shown promise as diagnostic markers and prognostic predictors in malignant mesothelioma (MM).
  • Through immunohistochemistry, we confirmed 40 cases of mesothelioma and 11 cases of adenocarcinoma, although we were unable to classify 7 of the 8 cases presenting atypical histologic patterns.
  • Cox multivariate analysis revealed that the risk factor for death was higher (476.2) among patients of advanced age, presenting the biphasic subtype and testing positive for components expressed at the nuclear level.
  • CONCLUSION: The most useful immunohistochemical markers were was calretinin (for mesothelioma) and CEA (for adenocarcinoma).
  • Immunohistochemical quantification of thrombomodulin facilitated the diagnosis of mesothelioma in patients testing positive for both calretinin and CEA.
  • Therefore, histopathological analysis offers a powerful weapon with great potential to inform decisions regarding the use of adjuvant chemotherapy after surgical excision of a mesothelioma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268732.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Leu-M1 antigen; 0 / S100 Calcium Binding Protein G; 0 / Thrombomodulin; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


54. Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M: Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res; 2009 Jan 1;15(1):382-9
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
  • EXPERIMENTAL DESIGN: Patients with malignant pleural mesothelioma or non-small cell lung cancer received pemetrexed doses from 500 to 900 mg/m(2) + 75 mg/m(2) cisplatin once every 21 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Glutamates / administration & dosage. Glutamates / pharmacokinetics. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy


55. Chamberlain MH, Fareed K, Nakas A, Martin-Ucar AE, Waller DA: Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2008 Jul;34(1):200-3
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma.
  • OBJECTIVES: In the preoperative workup for radical surgery for malignant pleural mesothelioma (MPM), mediastinal lymph node staging, diagnostic pleural biopsies and effusion control with talc pleurodesis are required.
  • Following conventional cervical videomediastinoscopy, a 5 mm thoracoscope was advanced into the relevant pleural cavity through the mediastinoscope via a mediastinal pleurotomy.
  • VACT is feasible in right-sided mesothelioma but has not yet been validated on the left.
  • [MeSH-major] Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Pleurodesis / methods. Thoracic Surgery, Video-Assisted / methods
  • [MeSH-minor] Adult. Aged. Biopsy. Drainage / methods. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pleural Effusion, Malignant / therapy. Talc / therapeutic use

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18450462.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 14807-96-6 / Talc
  •  go-up   go-down


56. Flores RM: Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer; 2005 Jul;49 Suppl 1:S71-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
  • Approximately 25% of patients with malignant pleural mesothelioma (MPM) prove unresectable at surgery and the median survival of stage III MPM is <12 months even after complete resection by extrapleural pneumonectomy.
  • Improving chemotherapy for MPM led us to test induction chemotherapy followed by EPP and adjuvant RT for locally advanced MPM to assess feasibility.
  • This combined modality approach is feasible for locally advanced MPM, and initial analysis suggests improved resectability.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15950805.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


57. Pilling J, Dartnell JA, Lang-Lazdunski L: Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg; 2010 Jun;58(4):215-9
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
  • INTRODUCTION: The results of trimodality therapy for malignant pleural mesothelioma (MPM) are related to stage.
  • CONCLUSIONS: In one of the few studies of integrated PET-CT in MPM that has complete pathological correlation we have shown that PET-CT does not accurately identify advanced tumor stage (T4) or mediastinal nodal disease (N2).
  • [MeSH-major] Fluorodeoxyglucose F18. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514576.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 14807-96-6 / Talc
  •  go-up   go-down


58. Tabata C, Hirayama N, Tabata R, Yasumitsu A, Yamada S, Murakami A, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Terada T, Nakano T: A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma. Eur Respir J; 2010 Nov;36(5):1099-105
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour associated with asbestos exposure that has only a limited response to conventional therapy; therefore, diagnosing MPM early is very important.
  • The patients with advanced-stage MPM showed higher levels of Ang-1 than the early-stage MPM patients and the Kaplan-Meier method revealed a significant correlation between serum Ang-1 levels and survival.
  • [MeSH-major] Angiopoietin-1 / blood. Angiopoietin-1 / genetics. Neoplasms, Mesothelial / metabolism. Pleural Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185425.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Biomarkers; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


59. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • RESULTS: We demonstrated that patients with MPM had significantly higher serum levels of VEGF than a population who had been exposed to asbestos but had not developed MPM, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage patients with MPM.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


60. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D: Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol; 2009 Jan;4(1):97-101
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
  • This class of compounds has demonstrated anticancer activity in malignant mesothelioma.
  • We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma.
  • METHODS: Patients with advanced mesothelioma, progression with one prior chemotherapy regimen and Eastern Cooperative Oncology Group performance status 0-2 were eligible.
  • CONCLUSIONS: Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma.
  • Evaluation of combination strategies or alternate dosing schedules may be necessary for further development of this novel agent in mesothelioma.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):804-10 [18245542.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):41-50 [11836668.001]
  • [Cites] Mol Cancer Ther. 2003 Feb;2(2):151-63 [12589032.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):721-8 [12939461.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91 [14715264.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1053-60 [3473246.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17174-9 [2211619.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7 [9501205.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3B):2063-8 [9677468.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):257-61 [16512979.001]
  • [Cites] J Transl Med. 2007;5:49 [17935615.001]
  • [Cites] Invest New Drugs. 2008 Feb;26(1):81-7 [17960324.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1400-10 [18027850.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):427-36 [11821955.001]
  • (PMID = 19096314.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01 CM062209; United States / NCI NIH HHS / CA / N01CM62209; United States / NCI NIH HHS / CM / N01 CM-62209
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Sulfonamides; F4H96P17NZ / belinostat
  • [Other-IDs] NLM/ NIHMS107784; NLM/ PMC3263397
  •  go-up   go-down


61. Rodríguez D, Cheung MC, Housri N, Koniaris LG: Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol; 2009 Jan 1;99(1):51-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant abdominal mesothelioma: defining the role of surgery.
  • OBJECTIVE: Determine the role of surgery for patients with malignant abdominal mesotheliomas (MAMs).
  • RESULTS: Overall, 10,589 cases of malignant mesotheliomas were identified.
  • Multivariate analysis identified that a poorly differentiated tumor grade, failure to undertake surgical resection, advanced age, and male gender were all independent predictors of poorer outcome.
  • [MeSH-major] Abdominal Neoplasms / surgery. Mesothelioma / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942074.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M: Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol; 2008 Feb;19(2):370-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
  • BACKGROUND: The aim of this study was to evaluate the activity and toxicity of pemetrexed and carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma (MPM).
  • PATIENTS AND METHODS: Patients with measurable advanced MPM and a zero to two Eastern Cooperative Oncology Group (ECOG) performance status (PS) were enrolled.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156144.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Historical Article; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


63. Uramoto H, Onitsuka T, Shimokawa H, Hanagiri T: TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed. Anticancer Res; 2010 Oct;30(10):4309-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
  • BACKGROUND: Recently, pemetrexed (PEM), a new generation antifolate, has been used for the treatment of patients with advanced non-squamous cell carcinoma (SQ) of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036757.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 0 / RNA, Messenger; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin; EC 1.5.1.3 / Tetrahydrofolate Dehydrogenase; EC 2.1.1.45 / Thymidylate Synthase; EC 2.1.2.2 / Phosphoribosylglycinamide Formyltransferase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


64. Spugnini EP, Crispi S, Scarabello A, Caruso G, Citro G, Baldi A: Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations. J Exp Clin Cancer Res; 2008;27:6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.
  • Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the deaths secondary to malignancy in humans.
  • After drainage of the malignant effusion from the affected cavity, the patients received four cycles of intracavitary CDDP at the dose of 50 mg/m2 every three weeks if dogs or four cycles of intracavitary carboplatin at the dose of 180 mg/m2 (every 3 weeks) if cats, coupled with daily administration of piroxicam at the dose of 0.3 mg/kg.
  • The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass.
  • The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Carboplatin / administration & dosage. Cat Diseases / drug therapy. Dog Diseases / drug therapy. Mesothelioma / veterinary. Piroxicam / administration & dosage. Pleural Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Intern Med. 1999 Nov-Dec;13(6):529-33 [10587251.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):443-9 [18365537.001]
  • [Cites] J Small Anim Pract. 2000 Aug;41(8):342-7 [11002935.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):311-7 [11165412.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3533-44 [12177114.001]
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):148-56 [12601280.001]
  • [Cites] Dtsch Tierarztl Wochenschr. 2003 Apr;110(4):177-8 [12756962.001]
  • [Cites] Vet Pathol. 1978 Nov;15(6):781-3 [751315.001]
  • [Cites] Nihon Juigaku Zasshi. 1982 Dec;44(6):975-9 [7182639.001]
  • [Cites] Nihon Juigaku Zasshi. 1985 Jun;47(3):511-6 [4032940.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):86-91 [3543239.001]
  • [Cites] J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 [2599941.001]
  • [Cites] Am J Vet Res. 1990 Oct;51(10):1682-7 [2240791.001]
  • [Cites] J Am Vet Med Assoc. 1991 May 1;198(9):1618-21 [2061177.001]
  • [Cites] J Vet Intern Med. 1991 Jul-Aug;5(4):227-31 [1658318.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1559-65 [8336195.001]
  • [Cites] J Comp Pathol. 1994 Nov;111(4):453-8 [7884062.001]
  • [Cites] Nat Med. 1997 Aug;3(8):913-6 [9256285.001]
  • [Cites] J Am Vet Med Assoc. 1997 Sep 15;211(6):736-40 [9301745.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666-80 [9603153.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2602-9 [15805256.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] J Feline Med Surg. 2005 Oct;7(5):313-6 [15914055.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):10120-1 [16267039.001]
  • [Cites] J Comp Pathol. 2006 May;134(4):347-54 [16712862.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):97-105 [16761625.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(12):2000-4 [16963313.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6133-43 [17062690.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):201-6 [10761756.001]
  • (PMID = 18577247.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2438333
  •  go-up   go-down


65. Pappa L, Machera M, Tsanou E, Damala C, Peschos D, Bafa M, Malamou-Mitsi V: Subcutaneous metastasis of peritoneal mesothelioma diagnosed by fine-needle aspiration. Pathol Oncol Res; 2006;12(4):247-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastasis of peritoneal mesothelioma diagnosed by fine-needle aspiration.
  • Mesothelioma is a rare malignant neoplasm of the serosal membranes, which can give distant metastases in various organs in advanced stages of its course.
  • In the literature, only one case of metastatic mesothelioma to the skin of the face has been reported.
  • We present a case of a 60-year-old female with a prior history of peritoneal malignant mesothelioma, who 6 months after the initial diagnosis presented with a subcutaneous nodule in the lateral chest wall.
  • Cytological examination of the material obtained by FNA from the nodule revealed metastatic mesothelioma.
  • Although subcutaneous metastasis of malignant mesothelioma is a rare entity, one must always keep this possibility in mind and proceed to further investigation of such lesions.
  • [MeSH-major] Mesothelioma / secondary. Peritoneal Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 2000 Jan-Feb;44(1):70-4 [10667164.001]
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Diagn Cytopathol. 1999 Jun;20(6):328-32 [10352904.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):223-4 [11373096.001]
  • [Cites] Am J Med. 1986 Jan;80(1):95-7 [3942156.001]
  • [Cites] Int J Surg Pathol. 2003 Jan;11(1):51-5 [12598922.001]
  • [Cites] Acta Cytol. 1987 Mar-Apr;31(2):185-93 [3469852.001]
  • [Cites] Respiration. 1987;51(4):266-71 [3659577.001]
  • [Cites] Am J Surg Pathol. 1991 Aug;15(8):779-84 [2069213.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Apr;126(4):435-7 [11997790.001]
  • [Cites] Cancer. 1976 Dec;38(6):2481-8 [826313.001]
  • [Cites] Am J Dermatopathol. 1997 Jun;19(3):261-5 [9185913.001]
  • [Cites] Acta Neuropathol. 1975 Dec 8;33(2):173-7 [1081808.001]
  • [Cites] Gastroenterology. 1972 Aug;63(2):346-50 [4558717.001]
  • [Cites] Am J Surg Pathol. 1990 Sep;14(9):819-28 [2389813.001]
  • [Cites] Pathologica. 2000 Aug;92(4):273-7 [11029888.001]
  • [Cites] J Cutan Pathol. 1992 Dec;19(6):490-5 [1487570.001]
  • [Cites] Am J Clin Pathol. 1992 Apr;97(4):493-7 [1553914.001]
  • [Cites] Environ Res. 1985 Dec;38(2):319-31 [4065080.001]
  • [Cites] Acta Cytol. 1988 Jul-Aug;32(4):567-75 [3041723.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1679-85 [2579718.001]
  • [Cites] J Surg Oncol. 1980;14(3):251-4 [7392647.001]
  • [Cites] Cancer. 1982 Jun 1;49(11):2431-5 [7074556.001]
  • [Cites] Br Med J. 1970 Dec 5;4(5735):575-8 [5485174.001]
  • [Cites] Jpn J Clin Oncol. 1996 Dec;26(6):469-71 [9001354.001]
  • [Cites] Cancer Res. 1970 May;30(5):1287-308 [4316726.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):818-20 [9622718.001]
  • [Cites] Cancer. 1970 Oct;26(4):914-9 [5506612.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):373S-376S [8462328.001]
  • [Cites] Chest. 1987 Feb;91(2):279-81 [3802946.001]
  • [Cites] Br J Dis Chest. 1976 Oct;70(4):246-50 [186091.001]
  • [Cites] Hum Pathol. 1992 Feb;23(2):107-16 [1740296.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • (PMID = 17189990.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Pehlivan B, Topkan E, Onal C, Nursal GN, Yuksel O, Dolek Y, Yavuz MN, Yavuz AA: Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma. Radiat Oncol; 2009;4:35
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.
  • BACKGROUND: When combined with adequate tumoricidal doses, accurate target volume delineation remains to be the one of the most important predictive factors for radiotherapy (RT) success in locally advanced or medically inoperable malignant pleural mesothelioma (MPM) patients.
  • [MeSH-major] Mesothelioma / radionuclide imaging. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiotherapy Planning, Computer-Assisted / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):6-7; discussion 8-9 [19695433.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):444-5 [11273069.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Eur J Radiol. 2002 Jan;41(1):1-9 [11750145.001]
  • [Cites] Radiother Oncol. 2002 Jan;62(1):51-60 [11830312.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1200-9 [12902408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):853-63 [14529793.001]
  • [Cites] Clin Lung Cancer. 2004 Mar;5(5):290-8 [15086967.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):78-86 [15093902.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Jul;96(1):171-7 [3386291.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1157-68 [2666592.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):4-9 [1689538.001]
  • [Cites] Radiology. 1991 Mar;178(3):705-13 [1847239.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9 [2072706.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):288-94; discussion 294-6 [8813257.001]
  • [Cites] Eur Respir J. 1996 Dec;9(12):2565-72 [8980970.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Thorac Surg Clin. 2004 Nov;14(4):567-73 [15559064.001]
  • [Cites] Clin Nucl Med. 2005 Jul;30(7):470-7 [15965321.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5063-8 [16707428.001]
  • [Cites] Cancer Treat Rev. 2006 Jun;32(4):245-60 [16563636.001]
  • [Cites] J Thorac Oncol. 2006 May;1(4):289-95 [17409872.001]
  • [Cites] Lung Cancer. 2007 Aug;57(2):125-34 [17478008.001]
  • [Cites] Radiother Oncol. 2008 Feb;86(2):251-7 [18207597.001]
  • [Cites] Med Dosim. 2008 Autumn;33(3):215-21 [18674686.001]
  • [Cites] Invest Radiol. 2008 Oct;43(10):737-44 [18791416.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:41 [18808725.001]
  • [Cites] Radiat Med. 2008 Dec;26(10):622-6 [19132495.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1413-8 [19224855.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3007-13 [19364962.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Apr;17(4):377-83 [10773558.001]
  • (PMID = 19758456.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2754492
  •  go-up   go-down


67. Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP, EORTC-NCIC: Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol; 2007 Dec 20;25(36):5770-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
  • PURPOSE: Malignant pleural mesothelioma (MPM) is a rare disease.
  • Unlike other advanced cancer types, little is known about patient-reported symptoms or health-related quality of life (HRQOL) and their possible prognostic value.
  • CONCLUSION: Results suggest that the PI, pain, and appetite loss may be independent prognostic factors in patients with advanced MPM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Quinazolines / therapeutic use. Thiophenes / therapeutic use

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089874.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA11488-30; United States / NCI NIH HHS / CA / 5U10CA11488-31; United States / NCI NIH HHS / CA / 5U10CA11488-32; United States / NCI NIH HHS / CA / 5U10CA11488-33; United States / NCI NIH HHS / CA / 5U10CA11488-34
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / Thiophenes; FCB9EGG971 / raltitrexed; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


68. Creaney J, Robinson BW: Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med; 2009 Jul;15(4):366-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum and pleural fluid biomarkers for mesothelioma.
  • PURPOSE OF REVIEW: Malignant mesothelioma is an asbestos-induced, aggressive tumour.
  • In centres across the world, research has focused on evaluating biomarkers for malignant mesothelioma screening, diagnosis, prognostication and monitoring.
  • With the incidence of malignant mesothelioma expected to increase, it is timely to review the current status of biomarkers in this field.
  • The assay sensitivity ranges from 50% at diagnosis to 84% in advanced disease.
  • SUMMARY: To date, soluble mesothelin remains the best available biomarker for malignant mesothelioma.
  • However, a lack of sensitivity for early-stage disease and for all malignant mesothelioma histologies provides motivation for the search of novel malignant mesothelioma biomarkers with greater sensitivity, especially for very early disease.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417672.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  • [Number-of-references] 52
  •  go-up   go-down


69. Tanaka A, Takahashi T: [Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis]. Nihon Kokyuki Gakkai Zasshi; 2009 May;47(5):383-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].
  • We report the case of a 68-year-old man with malignant pleural mesothelioma who was successfully treated with 4 lines of systemic chemotherapy and pleurodesis.
  • It is suggested that combination of several systemic chemotherapy lines and regional disease control such as pleurodesis may be effective for disease control in patients with advanced malignant pleural mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pleurodesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514499.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


70. Roberts HC, Patsios DA, Paul NS, DePerrot M, Teel W, Bayanati H, Shepherd F, Johnston MR: Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol; 2009 May;4(5):620-8
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure.
  • An interim limited computed tomography of the observed abnormality prompted 10 diagnostic biopsies, resulting in a diagnosis of six lung cancers, two pleural mesothelioma and two peritoneal mesothelioma; overall rate of screen-detected malignancies is 2.1%.
  • There were four interval cancers, diagnosed after baseline (n = 1) or after the annual repeat (n = 3): two pleural and one peritoneal mesothelioma, and one mixed squamous/small cell carcinoma.
  • CONCLUSION: Screening prior asbestos workers detects advanced malignant pleural mesothelioma and early as well as late stage lung cancer.
  • We expect to learn more about the appearance of "early mesothelioma" with continued screening.
  • [MeSH-major] Asbestos / adverse effects. Carcinogens. Lung Neoplasms / radiography. Mesothelioma / radiography. Occupational Exposure / adverse effects. Pleural Neoplasms / radiography. Tomography, X-Ray Computed


71. Lucchi M, Chella A, Melfi F, Dini P, Tibaldi C, Fontanini G, Mussi A: Four-modality therapy in malignant pleural mesothelioma: a phase II study. J Thorac Oncol; 2007 Mar;2(3):237-42
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four-modality therapy in malignant pleural mesothelioma: a phase II study.
  • BACKGROUND: Treatment approaches in malignant pleural mesothelioma (MPM) patients range from mere palliation to aggressive anticancer therapy, and there is currently no consensus on the optimal therapeutic strategy.
  • In 1999, we began a phase II study to investigate four-modality treatment of advanced stage MPM.
  • METHODS: From 1999 to 2004, 49 patients with International Mesothelioma Interest Group stage II-III MPM underwent four-modality treatment with intrapleural preoperative interleukin-2 (18 x 10(6) UI/day for 3 days), pleurectomy/decortication, intrapleural postoperative epidoxorubicin (25 mg/m2 for 3 days), interleukin-2 (18 x 10(6) UI/day for 3 days), adjuvant radiotherapy (30 Gy), systemic chemotherapy (cisplatin 80 mg/m2 day 1, gemcitabine 1250 mg/m2 days 1 and 8 for up to six courses) and long-term subcutaneous interleukin-2 (3 x 10(6) UI/day on 3 days per week).
  • CONCLUSION: The four-modality treatment that we adopted for advanced-stage MPM was feasible, well tolerated by most of the patients, and produced a favorable median survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410047.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


72. Edakuni N, Ikuta K, Yano S, Nakataki E, Muguruma H, Uehara H, Tani M, Yokota J, Aizawa H, Sone S: Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice. Oncol Res; 2006;16(5):235-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
  • Malignant pleural mesothelioma (MPM) is closely related to exposure to asbestos, and a rapid increase in the number of MPM patients is therefore estimated to occur from 2010 to 2040 in Japan.
  • The inactivation of the MYO18B gene plays an important role in several malignant diseases.
  • These findings suggest that the restored expression of MYO18B may be a useful therapeutic strategy for the treatment of locally advanced MPM in humans.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Lung Neoplasms / genetics. Mesothelioma / genetics. Myosins / genetics. Myosins / pharmacology. Pleural Effusion / genetics. Pleural Neoplasms / genetics. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / pharmacology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294804.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYO18B protein, human; 0 / Tumor Suppressor Proteins; EC 3.6.4.1 / Myosins
  •  go-up   go-down


73. Vachani A, Moon E, Wakeam E, Albelda SM: Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol; 2010 Apr;42(4):385-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene therapy for mesothelioma and lung cancer.
  • Both malignant pleural mesothelioma and advanced stage lung cancer are associated with a poor prognosis.
  • [MeSH-major] Genetic Therapy / methods. Lung Neoplasms / therapy. Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Respir Cell Mol Biol. 2010 Apr;42(4):383-4 [20228386.001]
  • (PMID = 20160042.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines; 0 / RNA, Antisense
  • [Number-of-references] 66
  •  go-up   go-down


74. Nakas A, Trousse DS, Martin-Ucar AE, Waller DA: Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg; 2008 Oct;34(4):886-91
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
  • OBJECTIVE: To identify the optimal debulking procedure in patients with malignant pleural mesothelioma who are not suitable for extrapleural pneumonectomy (EPP).
  • METHODS: We reviewed 102 consecutive patients (93 male; 9 female, mean age 63 years) who were not suitable for EPP because of either advanced tumour stage or suboptimal fitness.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656373.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Ambrosini V, Rubello D, Nanni C, Farsad M, Castellucci P, Franchi R, Fabbri M, Rampin L, Crepaldi G, Al-Nahhas A, Fanti S: Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma. Nucl Med Rev Cent East Eur; 2005;8(2):111-5
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
  • BACKGROUND: Despite being a relatively rare disease, the incidence of malignant pleural mesothelioma (MPM) is expected to increase over the next two decades due to the long time interval elapsing between exposure to causative factors, mainly asbestos, and disease onset.
  • In more advanced disease stages, a multimodality treatment, including various combinations of chemotherapy, external radiotherapy and surgery, may provide some favourable results though the prognosis remains poor.
  • [MeSH-major] Mesothelioma / radiography. Mesothelioma / radionuclide imaging. Pleural Neoplasms / radiography. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Subtraction Technique. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437396.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


76. Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G: Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial. In Vivo; 2006 Nov-Dec;20(6A):715-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
  • Malignant pleural mesothelioma (MPM) is an aggressive treatment-resistant tumor with a median survival from diagnosis of 12 months.
  • Although multimodality protocols that combine aggressive surgery and adjuvant chemotherapy or radiotherapy have shown improved survival in selected cases, the majority of patients with MPM are not suitable for radical surgery due to advanced stage and comorbid medical illness.
  • The aim of this phase I-II study was to evaluate the toxicity profile and efficacy of two different platinum-based combined regimens--cisplatin plus mitomycin-C (MMC) and cisplatin plus melphalan (L-PAM)--administered using TSP technique in patients with advanced or recurrent MPM who had refractory disease after systemic first line chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy


77. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM: Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther; 2007 Jul;6(7):1962-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
  • Malignant pleural mesothelioma (MPM) is a deadly disease with few systemic treatment options.
  • However, expression of activated Src (p-Src Y419) on the tumor cell membrane was higher in patients with advanced-stage disease; the presence of metastasis correlated with higher membrane (P = 0.03) and cytoplasmic (P = 0.04) expression of p-Src Y419.
  • Lower levels of membrane expression of inactive c-Src (p-Src Y530) correlated with advanced N stage (P = 0.02).
  • [MeSH-major] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Movement / drug effects. Mesothelioma / pathology. Pleural Neoplasms / pathology. Proto-Oncogene Proteins pp60(c-src) / antagonists & inhibitors. Pyrimidines / pharmacology. Thiazoles / pharmacology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17620427.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src); RBZ1571X5H / Dasatinib
  •  go-up   go-down


78. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR: A mouse model recapitulating molecular features of human mesothelioma. Cancer Res; 2005 Sep 15;65(18):8090-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model recapitulating molecular features of human mesothelioma.
  • Malignant mesothelioma has been linked to asbestos exposure and generally has a poor prognosis because it is often diagnosed in advanced stages and is refractory to conventional therapy.
  • Human malignant mesotheliomas accumulate multiple somatic genetic alterations, including inactivation of the NF2 and CDKN2A/ARF tumor suppressor genes.
  • To better understand the significance of NF2 inactivation in malignant mesothelioma and identify tumor suppressor gene alterations that cooperate with NF2 loss of function in malignant mesothelioma pathogenesis, we treated Nf2 (+/-) knockout mice with asbestos to induce malignant mesotheliomas.
  • Asbestos-exposed Nf2 (+/-) mice exhibited markedly accelerated malignant mesothelioma tumor formation compared with asbestos-treated wild-type (WT) littermates.
  • Loss of the WT Nf2 allele, leading to biallelic inactivation, was observed in all nine asbestos-induced malignant mesotheliomas from Nf2 (+/-) mice and in 50% of malignant mesotheliomas from asbestos-exposed WT mice.
  • For a detailed comparison with the murine model, DNA analyses were also done on a series of human malignant mesothelioma samples.
  • Remarkably, similar to human malignant mesotheliomas, tumors from Nf2 (+/-) mice showed frequent homologous deletions of the Cdkn2a/Arf locus and adjacent Cdkn2b tumor suppressor gene, as well as reciprocal inactivation of Tp53 in a subset of tumors that retained the Arf locus.
  • As in the human disease counterpart, malignant mesotheliomas from the Nf2 (+/-) mice also showed frequent activation of Akt kinase, which plays a central role in tumorigenesis and therapeutic resistance.
  • Thus, this murine model of environmental carcinogenesis faithfully recapitulates many of the molecular features of human malignant mesothelioma and has significant implications for the further characterization of malignant mesothelioma pathogenesis and preclinical testing of novel therapeutic modalities.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166281.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077429; United States / NIEHS NIH HHS / ES / ES-03721; United States / NCI NIH HHS / CA / R01 CA045745; United States / NCI NIH HHS / CA / CA-45745; United States / NCI NIH HHS / CA / CA77429; United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / CA-06927
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p14ARF; 12001-28-4 / Asbestos, Crocidolite
  •  go-up   go-down


79. Luckraz H, Rahman M, Patel N, Szafranek A, Gibbs AR, Butchart EG: Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg; 2010 Mar;37(3):552-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
  • BACKGROUND: Optimal management of diffuse malignant pleural mesothelioma (DMPM) remains unclear.
  • Surgical options were extra-pleural pneumonectomy (EPP) for Butchart stage I disease in clinically fit patients (n=49) or pleurectomy/decortication in patients who were either not fit for EPP or had advanced disease (Butchart stage II and III) or both (n=90).
  • CONCLUSIONS: In this series, cytoreductive surgery combined with post-operative adjuvant therapy provided better survival despite either advanced disease or surgically less fit patients.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Pneumonectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19717307.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


80. Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL: A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol; 2010 Oct;5(10):1655-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
  • HYPOTHESIS: Malignant mesotheliomas (MMs) express vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and cKIT.
  • We evaluated the activity of sorafenib in patients with unresectable mesothelioma.
  • CONCLUSION: Sorafenib has limited activity in advanced MM patients, similar to that seen with other VEGFR tyrosine kinase inhibitors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Pleural Neoplasms / drug therapy. Pyridines / therapeutic use

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):311-7 [11165412.001]
  • [Cites] Eur J Cancer. 2009 Sep;45(13):2304-11 [19502050.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2081-90 [19255316.001]
  • [Cites] Lung Cancer. 2009 Jan;63(1):94-7 [18486273.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1962-72 [17620427.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] Cancer Lett. 2006 Aug 8;239(2):183-9 [16216411.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):257-61 [16512979.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Lung Cancer. 2005 May;48(2):291-6 [15829331.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2221-30 [10327068.001]
  • [Cites] Clin Exp Metastasis. 1998 Aug;16(6):529-39 [9872600.001]
  • [Cites] Oncogene. 1991 Nov;6(11):2005-11 [1658707.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] J Pathol. 2001 Apr;193(4):468-75 [11276005.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 20736856.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA045389; United States / NCI NIH HHS / CA / U10 CA180821; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / R01 CA135257; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS229523; NLM/ PMC3823555
  •  go-up   go-down


81. Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, Hill R, McLeod C, Walley T: Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. Health Technol Assess; 2007 Jan;11(1):1-90
PubMed Health. PubMed Health .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
  • OBJECTIVES: To assess the clinical effectiveness and cost-effectiveness of pemetrexed disodium in combination with cisplatin for the treatment of unresectable pleural mesothelioma in chemotherapy-naive patients.
  • These findings were better for some patient subgroups, e.g. especially for fully supplemented (FS) patients with good performance status (0/1) and advanced disease (AD).
  • Cost-effectiveness seems better for some patient subgroups, e.g. especially for patients with good performance status and with advanced diseases, where it is estimated the ICER per QALY would be pound36,700.
  • Given the relatively small number of patients with mesothelioma, albeit increasing, the overall budget impact of pemetrexed would be unlikely to be more than pound5 million per year at present costs.
  • Much more research is needed into the optimum chemotherapy for patients with mesothelioma and a clear definition of what constitutes best supportive care.
  • [MeSH-major] Antineoplastic Agents / economics. Antineoplastic Agents / therapeutic use. Glutamates / economics. Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy


82. Belli C, Anand S, Panella M, Giovannini M, Tassi G, Fennell D, Mutti L: Will antiangiogenic agents be a future for mesothelioma therapy? Curr Med Chem; 2010;17(27):3069-79
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Will antiangiogenic agents be a future for mesothelioma therapy?
  • BACKGROUND: Malignant mesothelioma (MM) is an aggressive disease that is diagnosed mostly in locally advanced or metastatic stage.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Mesothelioma / drug therapy. Neovascularization, Pathologic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629625.001).
  • [ISSN] 1875-533X
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  •  go-up   go-down


83. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G, European Organisation for Research and Treatment of Cancer Lung Cancer Group, National Cancer Institute of Canada: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol; 2005 Oct 1;23(28):6881-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
  • PURPOSE: We conducted a phase III trial to determine whether first-line treatment with raltitrexed, a thymidine synthase inhibitor, and cisplatin results in superior outcome compared with cisplatin alone in patients with malignant pleural mesothelioma (MPM).
  • PATIENTS AND METHODS: Eligible patients with histologically proven advanced MPM, not pretreated with chemotherapy, WHO performance status (PS) 0 to 2, and adequate hematological, renal, and hepatic function were randomly assigned to receive cisplatin 80 mg/m2 IV on day 1, alone (arm A) or combined with raltitrexed 3 mg/m2 (arm B).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192580.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-30; United States / NCI NIH HHS / CA / 5U10-CA11488-34
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; FCB9EGG971 / raltitrexed; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


84. Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C: Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol; 2010 May 20;28(15):2604-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
  • Hypervascularity is a prominent and poor-prognosis feature of malignant pleural mesothelioma (MPM).
  • CONCLUSION: The tolerability and disease control of NGR-hTNF 0.8 microg/m(2) weekly warrant additional evaluation in patients with advanced MPM.
  • [MeSH-major] Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Recombinant Fusion Proteins / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406925.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / tumor necrosis factor-alpha, CNGRC fusion protein, human
  •  go-up   go-down


85. Harb A, King E, Lloyd H, Harb Z, Payne JG: Primary omental mesothelioma: a rare but important differential diagnosis in previous asbestos exposure. J Gastrointest Surg; 2010 Feb;14(2):423-5
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary omental mesothelioma: a rare but important differential diagnosis in previous asbestos exposure.
  • Primary omental mesothelioma is a malignant tumour of the mesothelial cells of the omentum, related to asbestos exposure.
  • We present a review of the related literature and report on a fatal case of primary omental mesothelioma in a 70 year old man, presenting with a painful abdominal mass.
  • The difficulty in diagnosis and management and the advanced stage of disease meant that prognosis was very poor.
  • [MeSH-major] Asbestosis. Mesothelioma / diagnosis. Occupational Exposure. Omentum / pathology. Peritoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Surg Today. 2004;34(9):780-3 [15338355.001]
  • [Cites] AJR Am J Roentgenol. 1984 Nov;143(5):1075-7 [6333150.001]
  • [Cites] Zentralbl Gynakol. 1983;105(9):598-601 [6880476.001]
  • (PMID = 19424765.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


86. Simon F, Johnen G, Krismann M, Müller KM: Chromosomal alterations in early stages of malignant mesotheliomas. Virchows Arch; 2005 Oct;447(4):762-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal alterations in early stages of malignant mesotheliomas.
  • In a case of a 67-year-old man with two different early stages of a predominantly epithelioid mesothelioma ("mesothelioma in situ", "early-stage mesothelioma"), chromosomal imbalances were determined by comparative genomic hybridisation (CGH), a molecular cytogenetic technique to detect chromosomal gains and losses in tumour cells.
  • In the case of the mesothelioma in situ cells, nine different chromosomal alterations could be detected (losses on 3p, 5q, 6q, 8p, 9p, 15q, 22q, Y; gain on 7q), whereas the early-stage mesothelioma showed the same defects except for the gain on 7q.
  • The simultaneous losses of 6q, 9p and 22q, as well as other chromosomal regions, correlate well with the most common defects previously found in 90 cases of more-advanced-stage mesotheliomas using CGH.
  • The molecular cytogenetic findings support the histological diagnosis of a pleural mesothelioma.
  • The surprisingly high number and extent of genomic alterations found in the examined case probably reflects the genomic instability in the tumour cells and indicates a "genetic chaos" even in earlier stages of malignant mesotheliomas.
  • [MeSH-major] DNA, Neoplasm / genetics. Mesothelioma / genetics. Mesothelioma / pathology. Pleural Neoplasms / genetics. Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1992 Jul;13(3):718-25 [1639399.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Hum Pathol. 1996 Apr;27(4):342-9 [8617476.001]
  • [Cites] Int J Oncol. 2003 May;22(5):1009-17 [12684666.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):248-55 [11037344.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Feb;18(2):94-101 [9115969.001]
  • [Cites] Br J Cancer. 1998;77(2):260-9 [9460997.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1159-61 [15475955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4494-9 [10200290.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Chest. 1996 Jan;109(1):109-14 [8549169.001]
  • [Cites] J Pathol. 2002 Jul;197(3):363-71 [12115883.001]
  • [Cites] Br J Cancer. 1997;75(1):79-86 [9000602.001]
  • [Cites] J Mol Diagn. 2000 Nov;2(4):209-16 [11232111.001]
  • [Cites] J Pathol. 1999 Oct;189(2):150-4 [10547567.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Semin Diagn Pathol. 1992 May;9(2):151-61 [1609157.001]
  • (PMID = 16012846.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


87. Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, Di Marino M, di Crescenzo VG, Visca P, Menegozzo S, Spugnini EP, Citro G, Ceribelli A, Mirri A, Chien J, Shridhar V, Ehrmann M, Santini M, Facciolo F: The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics; 2008 Aug;9(8):1069-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The serine protease HtrA1 is a novel prognostic factor for human mesothelioma.
  • AIMS: The objective of our study was to analyze the potential prognostic value of the expression of the serine protease HtrA1 and of EGFR in 70 malignant mesotheliomas.
  • Moreover, extension of the tumor (T) and involvement of lymph nodes (N) advanced status (p = 0.001 and 0.002, respectively), as well as the sarcomatoid histotype (p = 0.005), correlated significantly with poor survival.
  • CONCLUSION: This is the first study of the relationship between HtrA1 expression and survival of mesothelioma patients.
  • The data obtained strongly indicate the utilization of HtrA1 expression as a prognostic parameter for mesothelioma and suggest this serine protease as a possible molecular target for the treatment of malignant mesotheliomas.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / enzymology. Serine Endopeptidases


88. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res; 2007 Sep 1;13(17):5144-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
  • EXPERIMENTAL DESIGN: SS1P given as a 30-min i.v. infusion every other day (QOD) for six or three doses was administered to 34 patients with advanced mesothelioma (n = 20), ovarian (n = 12), and pancreatic (n = 2) cancer.
  • Phase II clinical trials of SS1P are being planned for malignant mesothelioma and other mesothelin-expressing malignancies.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Immunotoxins / administration & dosage. Mesothelioma / drug therapy. Ovarian Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785569.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunotoxins; 0 / SS1(dsFv)PE38
  •  go-up   go-down


89. Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX: Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. Cancer Chemother Pharmacol; 2007 Jul;60(2):203-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
  • Disease stabilization was seen in four subjects with the following tumors: mesothelioma (14 cycles), chondrosarcoma (12 cycles), small cell carcinoma (10 cycles), and prostate carcinoma (6 cycles).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091249.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / MAC321; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


90. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C: Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer; 2009 Nov;66(2):141-9
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed in the treatment of advanced non-squamous lung cancer.
  • Firstly, pemetrexed was approved in combination with cisplatin for the treatment of malignant pleural mesothelioma.
  • The next step was to test pemetrexed plus cisplatin versus gemcitabine plus cisplatin, as first-line therapy in advanced NSCLC patients, in a phase III, non-inferiority, randomized trial.
  • The role of pemetrexed as maintenance therapy after first-line therapy for advanced NSCLC is currently being evaluated into a phase III trial.
  • To date, pemetrexed is registered, at the dose of 500 mg/m(2) on day 1 of a 3-week schedule, in combination with cisplatin, for first-line therapy and, as single-agent, for second-line treatment of patients with non-squamous NSCLC.This review shows the latest and indicates the future developments of pemetrexed in the treatment of advanced NSCLC patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577816.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biological Products; 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 59
  •  go-up   go-down


91. Cicenas S, Vencevicius V: [Malignant pleural diseases: diagnosis and treatment]. Medicina (Kaunas); 2008;44(12):929-35
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural diseases: diagnosis and treatment].
  • OBJECTIVE: To evaluate efficacy of diagnostic procedures, results of surgery, and complications in malignant pleural diseases.
  • Patients were divided into two groups: group I, patients with primary pleural malignant diseases (93 patients, 55.0%), and group II, secondary pleural tumors (76 patients, 45%).
  • In all 36 patients (100.0%) with chest wall tumors, disease of advanced stage was determined.
  • After 169 operations due to malignant pleural diseases, the rate of postoperative complications ranged from 1.3% to 7.8%.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142050.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


92. Bozóky G, Ruby E, Góhér I, Mohos A, Bálint C, Bozóky I: [Disorders of hemostatic system in patients with malignant disease, especially in view of venous thromboembolism]. Orv Hetil; 2007 Sep 9;148(36):1691-7
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disorders of hemostatic system in patients with malignant disease, especially in view of venous thromboembolism].
  • INTRODUCTION: An increased susceptibility to thrombosis demonstrated in laboratory analysis of solid malignant diseases develops as a result of the activating effect of malignant cells on the hemostatic system.
  • The development of this activating effect is a consequence of interactions between malignant cells and the various components of the coagulation system (coagulation factors, platelets, endothelial cells, fibrinolytic system) which leads from a prothrombotic state to clinically identifiable disorders of the hemostatic system.
  • AIMS: In a retrospective analysis, authors sought to answer what characteristics and frequency of hemostatic disorders developed in a great number of cases with malignant diseases.
  • METHOD: Between 1996 and 2004, solid malignant diseases were diagnosed in 1381 patients by histological and/or cytological examinations.
  • In the rest of the cases, malignant processes were located in breast, colorectal system, kidney, bladder, thyroid gland and pancreas.
  • Mesothelioma was diagnosed in six patients by histological analysis.
  • Based on the examinations of clinical stage-definition, the malignant disease was in an advanced stage.
  • The role of existing non-malignant associative diseases concerning the development of hemostatic disorders was also given a special attention.
  • RESULT: Out of the 1381 patients with malignant disease, clinically identifiable hemostatic disorders were found in 397 cases (28.7%).
  • Hypercoagulable state in patients with malignant disease may result in the occurrence of various clinically identifiable hemostatic system disorders: the most frequent one is venous thromboembolism (so-called secondary thrombosis).
  • In cases of idiopathic venous thromboembolism, it is recommended to carry out specific clinical check-up to prove or to preclude asymptomatic malignant diseases.

  • MedlinePlus Health Information. consumer health - Bleeding Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766220.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


93. Okishiro N, Tanimukai H, Tsuneto S, Ito N: Can "steroid switching" improve steroid-induced psychosis in a patient with advanced cancer? J Palliat Med; 2009 May;12(5):487-90
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can "steroid switching" improve steroid-induced psychosis in a patient with advanced cancer?
  • We experienced the case of 67-year-old man with malignant pleural mesothelioma and pulmonary emphysema who developed psychiatric symptoms after switching from oral prednisolone 10 mg/day to intravenous betamethasone 2 mg/day.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BETAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416050.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 9842X06Q6M / Betamethasone; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


94. Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB, Yuan Z, Sanchez-Torres JM: Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res; 2010 May 15;16(10):2872-80
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC.
  • EXPERIMENTAL DESIGN: Patients with TSF (pleural effusions, ascites) and relapsed, stage III/IV NSCLC or malignant pleural/peritoneal mesothelioma were treated with pemetrexed (500 mg/m2) on day 1 of each 21-day cycle.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Ascites / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / pharmacokinetics. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Effusion, Malignant / drug therapy

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR.
  • (PMID = 20460481.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


95. Bellmunt J, Delgado FM, George C: Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Semin Oncol; 2008 Jun;35(3 Suppl 3):S34-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors.
  • Vinflunine is active against a variety of tumor types, including advanced TCCU, metastatic breast cancer, advanced non-small cell lung cancer, and malignant pleural mesothelioma.
  • Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Small Cell / drug therapy. Clinical Trials as Topic. Humans. Mesothelioma / drug therapy. Mice. Pleural Neoplasms / drug therapy. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538178.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Tubulin Modulators; 5BF646324K / vinflunine; 5V9KLZ54CY / Vinblastine
  • [Number-of-references] 52
  •  go-up   go-down


96. Słodkowska J, Patera J, Breborowicz J, Jarzemska A, Korzeniewska-Kosela M, Siemiatkowska K, Radzikowska E, Przybylski G, Kozłowski W: Extrapulmonary lymphangioleiomyomatosis presented as the asymptomatic retroperitoneal tumours--two cases report. Pol J Pathol; 2006;57(4):205-7
Genetic Alliance. consumer health - Lymphangioleiomyomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumours were surgically removed and diagnosed as: 1-malignant mesothelioma and 2-tymphangiomyoma.
  • The microscopical sections were reviewed and re-diagnosed as e-LAM at advanced pulmonary LAM development.
  • [MeSH-minor] Adult. Diagnosis, Differential. Disease Progression. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lymphangiomyoma / diagnosis. Lymphangiomyoma / pathology. Mesothelioma / diagnosis. Mesothelioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pol J Pathol. 2007;58(2):105 [17715677.001]
  • (PMID = 17285764.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Duplicate Publication; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


97. Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther; 2005 Sep;27(9):1343-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The US Food and Drug Administration approved pemetrexed in February 2004 for the treatment of malignant pleural mesothelioma (MPM) in combination with cisplatin in patients with unresectable disease or for whom curative surgery is not an option.
  • In August 2004, pemetrexed was approved as a second-line, single-agent treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
  • Search terms included pemetrexed, Alimta, MTA, multitargeted antifolate, LY231514, mesothelioma, MPM, non-small cell lung cancer, NSCLC, breast cancer, and pancreatic cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Folic Acid Antagonists / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291410.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 162
  •  go-up   go-down


98. Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC: Pemetrexed-induced pneumonitis: a case report. Clin Lung Cancer; 2009 Sep;10(5):364-6
Hazardous Substances Data Bank. CIPROFLOXACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology.
  • Because pemetrexed is being prescribed with increasing frequency for NSCLC and mesothelioma, we believe that physicians should be aware of this rare but serious complication.

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19808196.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Infective Agents; 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5E8K9I0O4U / Ciprofloxacin; 5Z93L87A1R / Guanine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


99. Sudoh J, Gemma A: [Pemetrexed]. Gan To Kagaku Ryoho; 2008 Jun;35(6):1033-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pemetrexed (ALIMTA, LY231514) is a novel, multi targeted antifolate chemotherapy agent that is active in various tumors including mesothelioma, NSCLC, breast, colon and bladder carcinoma.
  • Pemetrexed is approved in the United States and a number of European Union countries for use in the treatment of mesothelioma, and the second-line treatment of advanced NSCLC.
  • However, in Japan, pemetrexed was approved for use only in combination with cisplatin in the treatment of mesothelioma in January 2007.
  • This approval was granted on the basis of a phase III trial of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633241.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


100. Davidson B: Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog; 2007 Dec;13(3):189-227
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of cancer cells in effusions within the serosal (peritoneal, pleural, and pericardial) cavities is a clinical manifestation of advanced-stage cancer and is associated with poor survival.
  • Tumor cells in effusions most frequently originate from primary carcinomas of the ovary, breast, and lung, and from malignant mesothelioma, a native tumor of this anatomic site.
  • In recent years, we have studied the biological characteristics of ovarian carcinoma, breast carcinoma, and malignant mesothelioma cells in effusions and compared it to their counterparts in primary tumors and solid metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298385.001).
  • [ISSN] 0893-9675
  • [Journal-full-title] Critical reviews in oncogenesis
  • [ISO-abbreviation] Crit Rev Oncog
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / Cell Adhesion Molecules; 0 / Cytokines; 0 / EFN-4 protein, C elegans; 0 / Ephrins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Receptors, Growth Factor
  • [Number-of-references] 167
  •  go-up   go-down






Advertisement